Physicians' Academy for Cardiovascular Education

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD - Monash University, Melbourne, Australia

Video navigation menu

  • Epidemiology of CKD 00:32
  • Treatment options for DKD 02:23
  • Newer treatment options: GLP-1RAs and SGLT2 inhibitors 06:12
  • Ongoing SGLT2i trials enrolling CKD/DKD patients 11:18
  • EASD/ADA consensus report on choice of second-line therapy  12:07

Which statement is true about renal outcomes of recent SGLT2i trials?

  • A. Decline in eGFR was larger in macroalbuminuria patients on canagliflozin in CREDENCE
  • B. In EMPA-REG OUTCOME, patients with macroalbuminuria had renal benefit with empagliflozin
  • C. Use of SGLT2i in EMPA-REG OUTCOME, DECLARE-TIMI 58 and CANVAS resulted in CV benefit, but not renal benefit
  • D. A meta-analysis of four SGLT2i trials showed heterogeneity of renal outcomes with SGLT2i use
Show the correct answer

Educational information

This lecture by Mark Cooper was part of the EBAC-accredited symposium "Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i" held during the virtual ERA EDTA 2020 meeting.


Prof. Mark Cooper, MD - Inaugural Head of the Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of the presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: